Temporal Trends and Projections of Bladder Cancer Burden in China from 1990 to 2030: Findings from the Global Burden of Disease Study

Xiang, Zhisheng; Ye, Zijie; Ma, Jingyu; Lin, Yongtian; Zhou, Yan

doi:10.2147/clep.s387289

Cited by 11 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If both the AAPC and the upper limit of 95% CI are less than 0, the estimated value is considered to have a downward trend. Otherwise, indicators are considered stable for a long time 22 . Figures were designed with Excel 2016 (Figures 1–3).…”

Section: Methodsmentioning

confidence: 99%

Current status and temporal trend in incidence, death, and burden of esophageal cancer from 1990−2019

et al. 2023

View full text Add to dashboard Cite

BackgroundEsophageal cancer (EC) is one of the world's most unknown and deadly cancers. This study aimed to provide updated epidemiological indicators and the recent trend of EC by age group, gender, and geographical region in the world.MethodsAnnual case data and age‐standardized rates (ASRs) of epidemiological indicators of EC were collected from the 2019 Global Burden of Disease (GBD) study from 1990 to 2019 in 204 countries and territories based on the sociodemographic index (SDI). Relative difference (%), average annual percentage change (AAPC), and the male/female ratio were calculated. Data are reported in values and 95% confidence interval (CI).ResultsEC age‐standardized incidence rates (ASIR) decreased by 19%, age‐standardized death rates (ASDR) decreased by 25%, and disability‐adjusted life‐years ASR (DALYs ASR) decreased by 30% from 1990 to 2019. The higher number of EC cases was in men aged 50 to 69 years and in women aged over 70. From 1990 to 2019, Middle SDI countries experienced a decline in the ASIR and ASDR of EC. The High SDI countries had an increasing ASDR trend. In World Bank High‐Income countries, the ASIR of EC has remained unchanged and decreased in other regions. The Asia continent has the highest rate of incidence, mortality, and burden of EC and the highest rate of reduction. East Asia, Southern Sub‐Saharan Africa, and Eastern Sub‐Saharan Africa respectively have the highest ASIR of EC. Central Asia has experienced the greatest decrease in the ASIR and ASDR of EC, the countries of Central Europe had a steady ASIR and High‐Income North America had an increasing trend in ASIR and ASDR. The burden of EC shows a decreasing trend worldwide. Central and East Asia regions have the highest rate and the highest increase in the burden of EC.ConclusionBased on great variation in the geographical distribution of epidemiological indicators of EC, investigating the reasons for this diversity requires more studies to be conducted in the field of prevention, distribution of risk factors, and implementation of screening methods with high cost‐effectiveness, and access to treatment methods. The provision of regional solutions may be more effective than global strategies.

show abstract

Section: Methodsmentioning

confidence: 99%

Current status and temporal trend in incidence, death, and burden of esophageal cancer from 1990−2019

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is the thirteenth for the cause of cancer-related death [7]. In China, the incidence and mortality of bladder cancer is first among the urinary system tumors, and with the advancement and changes in the lifestyle habits, the incidence and detection rate of bladder cancer has been increasing year by year [7,8].…”

Section: Concepts On Bladder Cancer and Epidemiology Characteristicsmentioning

confidence: 99%

The Recent Research Progress of CircRNA in Bladder Cancer

Liu¹,

Xu²

2023

ann urol oncol

View full text Add to dashboard Cite

Bladder cancer is a major public health problem in the world, and is one of the most common malignant tumors in the genito-urinary system. Due to its high incidence and mortality, it remains a serious threat to human health. In recent years, related researches on the occurrence of bladder cancer found a certain connection between the expression level of circRNA and development of bladder cancer. circRNA can accomplish the purpose of promoting or inhibiting the occurrence and progression of bladder cancer by affecting the expression of related miRNA and mRNA. Higher expression levels of some circRNAs such as circITCH, circACVR2A, circPICALM, and circZKSCAN1 demonstrate an improved prognostic survival of patients with bladder cancer. Higher expression of circBPTF and circPRMT5 correlated with worse prognosis in bladder cancer patients. This article highlights a relationship between CircRNA and bladder cancer.

show abstract

“…In 2022, statistics projected approximately 92,000 new bladder cancer cases in China, leading to about 43,000 deaths. Influenced by the aging population and urbanization, both incidence and mortality rates of bladder cancer in China are projected to rise further 2,3 . Currently, platinum‐based combination chemotherapy is the standard treatment for locally advanced or metastatic UC (la/mUC), offering a median progression‐free survival (mPFS) of 7.6–8.3 months 1,4 .…”

Section: Introductionmentioning

confidence: 99%

“…Influenced by the aging population and urbanization, both incidence and mortality rates of bladder cancer in China are projected to rise further. 2 , 3 Currently, platinum‐based combination chemotherapy is the standard treatment for locally advanced or metastatic UC (la/mUC), offering a median progression‐free survival (mPFS) of 7.6–8.3 months. 1 , 4 Following the results from the Polaris‐03 and BGB‐A317‐204 studies, immune checkpoint inhibitors (ICIs) toripalimab and tislelizumab were approved as second‐line treatments for mUC, establishing a new standard for second‐line treatment in China.…”

Section: Introductionmentioning

confidence: 99%

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Xu,

Zhang,

Zhang

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

IntroductionPrevious RC48 (Disitamab Vedotin) studies established that the safety and efficacy of RC48‐antibody–drug conjugate (ADC), either alone or combined with toripalimab, for metastatic urothelial carcinoma (mUC) patients exhibiting human epidermal growth factor receptor 2 (HER2)‐positive or even HER2‐negative status after standard chemotherapy failure.MethodsWith locally advanced or metastatic urothelial carcinoma (la/mUC), patients who received RC48‐ADC monotherapy or a combination with programmed cell death protein 1 (PD‐1) inhibitors between August 2021 and October 2022 were enrolled in this retrospective observational study to evaluate the real‐world antitumor effectiveness and safety.ResultsAmong the 38 enrolled patients (29 males; median age 67.5 years [38–93]), 8 received RC48‐ADC monotherapy, while 30 received combination therapy. Initially, 63.2% (24/38) of the patients had received ≥1 line of prior treatment, and 63.2% (24/38) had visceral metastasis. UC of the bladder represented the majority type in 68.4% (26/38) of cases. By the data cutoff in March 2023, the overall objective response rate (ORR) was 63.2% (95% CI, 47.1%–79.2%), with a disease control rate (DCR) of 89.5% (95% CI, 79.3%–99.7%). Median follow‐up time was 10.6 months. The median progression‐free survival (PFS) was 8.2 months (95% CI, 5.9–10.5), with a 6‐month PFS rate of 63.2% and a 12‐month PFS rate of 34.1%. Median overall survival (OS) was not reached, with a 12‐month OS rate of 76.7%. The median duration of response was 7.3 months (95% CI, 4.6–10.0) among 24 patients evaluated as partial response (PR). The most common treatment‐related adverse events (TRAEs) included anemia (71.1%), anorexia (57.9%), asthenia (52.6%), hypoesthesia (52.6%), bone marrow suppression (47.4%), alopecia (47.4%), nausea (44.7%), proteinuria (36.8%), vomiting (34.2%), and hypoalbuminemia (31.6%). No patient experienced TRAEs of Grade ≥3. One patient had an immune‐related adverse event (irAE) of rash related to toripalimab.ConclusionsBoth as monotherapy and in combination with PD‐1 inhibitors, RC48‐ADC exhibits promising effectiveness and manageable safety profile for mUC patients in real‐world settings.

show abstract

Temporal Trends and Projections of Bladder Cancer Burden in China from 1990 to 2030: Findings from the Global Burden of Disease Study

Cited by 11 publications

References 38 publications

Current status and temporal trend in incidence, death, and burden of esophageal cancer from 1990−2019

Current status and temporal trend in incidence, death, and burden of esophageal cancer from 1990−2019

The Recent Research Progress of CircRNA in Bladder Cancer

Real‐world effectiveness and safety of RC48‐ADC alone or in combination with PD‐1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study

Contact Info

Product

Resources

About